PI-273 is the first reversible and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, which can inhibit the proliferation of breast cancer cells, block the cell cycle, and induce apoptosis.

 

Brand: BCM

 

Target: Apoptosis; PI4K

 

Signaling Pathways: Apoptosis; PI3K/Akt/mTOR signaling

 

pKa: 8.09±0.70(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water.

 

GHS: GHS05,GHS07,GHS09

 

Isomeric SMILES: CCC1=C(SC(=C1C(=O)N)NC(=S)NC(=O)C2=CC=C(C=C2)Cl)C  

 

InChIKey: MIERMBQDBLFAFW-UHFFFAOYSA-N  

 

InChI: InChI=1S/C16H16ClN3O2S2/c1-3-11-8(2)24-15(12(11)13(18)21)20-16(23)19-14(22)9-4-6-10(17)7-5-9/h4-7H,3H2,1-2H3,(H2,18,21)(H2,19,20,22,23)

 

Attribute
[Chem Name]	2-[(4-chlorobenzoyl)carbamothioylamino]-4-ethyl-5-methylthiophene-3-carboxamide
[Synonym]	PI-273
[CAS No.]	925069-34-7
[MDL No.]	MFCD08719772
[Formula]	C16H16ClN3O2S2
[Molecular]	381.9
[Form]	Solid Powder
[Storage]	Sealed in dry, 2-8°C

Goods Tag